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Barrett's oesophagus patients accumulate chromosomal
defects during the histological progression to cancer, one
of the most prominent of which is the amplification of
the whole of chromosome 4. We aimed to study the role
that the transcription factor NF-kB, a candidate cancer-
promoting gene, present on chromosome 4, plays in Barrett's
oesophagus, using OE33 cells as a model. Specifically, we
wanted to determine if NF-kB was activated by exposure to
bile acid (deoxycholic acid) in oesophageal cells. We
employed pathway specific cDNA microarrays and real-
time PCR, to first identify bile acid induced genes and
specifically to investigate the role of NF-kB. An NF-kB
reporter system was used, as well as an inhibitor of NF-
kB (pyrrolidine dithiocarbamate) to confirm the activation
of NF-kB by bile. We show that physiological levels of DCA
(100--300 mM) were capable of activating NF-kB in OE33
cells and inducing NF-kB target gene expression (particu-
larly IkB and IL-8). Other gene expression abnormalities
were also shown to be induced by DCA. Importantly, pre-
liminary experiments showed that NF-kB activation by bile
occurred at neutral pH, but not at acid pH. Acidic bile did
however cause over-expression of the c-myc oncogene, as
reported previously. Hence, we present data showing that
NF-kB may be a key mediator of carcinogenesis in bile
exposed Barrett's tissues. In addition, neutral bile acids
appear to play a significant part in reflux induced gene
expression changes. We postulate that the activation of the
survival factor NF-kB by bile may be linked to the previous
cytogenetic data from our laboratory showing the amplifi-
cation of NF-kB's chromosome (chromosome 4), during
Barrett's cancer progression. Hence chromosome 4 ampli-
fication may provide a survival mechanism for bile exposed
oesophageal tissues via NF-kB.
Introduction
The incidence of adenocarcinoma of the oesophagus is
increasing dramatically amongst Western populations. A
major risk factor for oesophageal adenocarcinoma is the pre-
sence of intestinal metaplasia in the lower oesophagus (so-
called Barrett's oesophagus). Barrett's oesophagus is caused
by prolonged reflux of stomach and duodenal contents and has
been reported in up to12% of patients undergoing endoscopy
for reflux symptoms (1). In order to provide adequate surveil-
lance for the increasing Barrett's population it is evident that
molecular markers of cancer progression are needed (2). A
number of specific molecular alterations have already been
shown to be correlated with cancer development in Barrett's
tissues (2--4). As well as serving as predictive markers of
cancer development, these molecular alterations, may help us
to understand the mechanism of cancer development and pro-
vide the basis for intervention strategies in the future.
In terms of cancer initiation and promotion in Barrett's
tissues, it is becoming accepted that refluxed bile acids play
a significant role (5--7). Barrett's metaplasia patients have
increased bile exposure and increased proportions of second-
ary bile acids in particular in their refluxate (8). Furthermore,
Barrett's patients with early adenocarcinoma have higher
exposure to bile acids than uncomplicated Barrett's patients
(9). Unconjugated bile acids in particular have been suggested
as an important factor in the progression of the neoplastic
sequence in Barrett's cancers (10,11). Opinion is still divided
as to the relative roles that bile acids and stomach acid play
(12). However, due to the fact that patients undergoing acid
suppression therapy still progress to adenocarcinoma, it sug-
gests that factors other than acid are important in Barrett's
carcinogenesis. Bile acids are known to be capable of inducing
DNA damage (13), chromosome aberrations (14), as well as
causing gene expression abnormalities (15,16); hence bile
acids are promising candidates as oesophageal carcinogens.
When coupled to the compensatory proliferation, which has
been postulated to occur in vivo as a result of bile induced
apoptosis (17), we can see a picture of bile as both an initiator
and promoter of cancer development.
Our previous cytogenetic studies of Barrett's progression
have identified two particular chromosomal abnormalities,
which appear to be intrinsically linked to cancer progression.
We have shown that chromosome 4 and chromosome 8 are
specifically amplified during cancer development (18,19). In
the case of chromosome 8 amplification, it can be readily
explained by the presence of the c-myc oncogene on its q arm
at locus 8q24, which has been linked previously to Barrett's
progression (15). This amplification has also been noted by
other researchers (20,21). However, the finding of chromo-
some 4 amplification in Barrett's patients is, as far as we are
aware, unique to our laboratory and has no obvious mechan-
istic basis. Hence, we have been looking to identify candidate
cancer-promoting genes on chromosome 4.
NF-kB is an anti-apoptotic, pro-inflammatory transcription
factor present on chromosome 4, whose increased activity has
been linked to many types of cancer (22). Figure 1 illustrates
one of the possible activation pathways of NF-kB. NF-kB
when activated enters the nucleus and switches on its target
genes, hence NF-kB is controlled post-translationally and does
not require de novo gene expression. There is already some
evidence that NF-kB may play a role in Barrett's progressionAbbreviation: DCA, deoxycholic acid.
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(23,24). There are also reports of the up-regulation of several
members of the NF-kB pathway during cancer development in
Barrett's patients. For example, TNF, an upstream activator of
NF-kB, has been shown to be progressively up-regulated in
Barrett's tissues (25) and IL-8, a downstream transcriptional
target of NF-kB has also been shown to be up-regulated in
Barrett's related adenocarcinomas (23). Finally, there are
reports that bile acids are capable of activating NF-kB in
colon cancer cell (26,27) and hepatocytes (28). Therefore, it
is possible that refluxed bile acids may be involved in NF-kB
activation in Barrett's tissues.
In this study we have taken a gene expression approach in
order to answer two inter-related questions. First, using cul-
tured oesophageal cells, are bile acids responsible for gene
expression abnormalities known to be present in Barrett's
tissues? Secondly, is NF-kB specifically activated in bile
exposed cells?
Materials and methods
Cell culture
OE33 cells derived from a Barrett's related adenocarcinoma were purchased
from the European Collection of Cell Cultures (Salisbury, UK). These cells,
which are basically tetraploid, were chosen due to their widespread use as
models of oesophageal cancer and due to our experience of them in previous
studies (14). Cells were grown in 25 ml of RPMI 1640 (Life Technologies,
Paisley, UK), supplemented with 1% glutamine and 10% bovine calf serum
(Life Technologies). The cells were grown in a humidified atmosphere of 5%
CO2/95% air at 37
C. Cells were detached from the flasks prior to subculturing
by the removal of the medium and the addition of 10 ml of trypsin (0.25%
trypsin in Hanks solution) for 5--10 min.
Treatment of the OE33 cells
Sub-confluent OE33 cells were treated with varying concentrations
(100--300 mM) of the bile acid deoxycholic acid (DCA) (Sigma, Poole, UK) in
serum-free medium for the allotted period of time (0--24 h) at 37C. These
doses of DCA were chosen from previous studies of DCA induced chromoso-
mal damage (14). In order to study the effect of acidified bile on OE33 cells,
the pH of the serum-free medium was adjusted to the desired level with
concentrated HCl prior to the addition of DCA. Furthermore, in the case of
treatment with the inhibitor of NF-kB, i.e. pyrrolidine dithiocarbamate (PDTC)
(Sigma), it was added at a concentration of 1 or 10 mM, shown previously to be
effective at inhibiting NF-kB (26), along with the specified dose of DCA.
RNA extraction and reverse transcription
The OE33 cells were subject to RNA extraction through the use of a Midi
RNeasy RNA extraction kit (Qiagen, Crawley, Surrey, UK). The extracted
RNA was subsequently DNase treated using a DNA-free kit (Ambion,
Huntingdon, UK). The RNA quantity was assessed by spectrophotometry at
260 nm and RNA quality was assessed by RT--PCR using primers for b-actin
DNA (forward: gatggccacggctgcttc, reverse: tgcctcagggcagcggaa). Reverse
transcription of the RNA samples (100--500 ng) was carried out for 60 min at
42C using a Retroscript RT kit (Ambion). PCR was subsequently carried out
using both cDNA and RNA to confirm the success of the DNase treatment.
Membrane array analysis
Gene expression analysis was carried out using a number of pathway-specific
Q series GEA membrane arrays (Superarray, Frederick, MD) containing
96 genes from each particular pathway. Total RNA (2 mg) was labelled with
Biotin UTP (Roche, Mannheim, Germany) during reverse transcription with
Superscript RNA Hÿ (Invitrogen, Paisley, UK). The labelled cDNA was then
hybridized onto the membranes overnight following the manufacturer's
instructions. Post-hybridization washes and a blocking step were carried out,
followed by chemiluminescent detection of hybridized signals. Arrays were
then exposed to hyperfilm ECL (Amersham Biosciences, Bucks, UK) and the
film was developed using a Curix 60 automatic developer (Agfa, Mortsel,
Belgium). The arrays all contained 10 housekeeping genes in addition to the 96
pathway specific genes; this allowed the RNA quality and the success of the
labelling to be monitored in each experiment. Array experiments were per-
formed in duplicate to ensure that only consistent gene expression changes
were identified. The arrays used in this study included a Cancer Pathway array,
a Signal Tranduction array, a NF-kB array, a Cell Cycle array and a
Chemokine/Chemokine Receptor array.
Real-time PCR
The RNA (2 mg) was first reverse transcribed into cDNA using a Retroscript
RT kit (Ambion) as detailed above. Real-time PCR was then carried out using
an iCycler PCR machine (Bio-Rad, Hemel Hempstead, UK). The PCR primers
used in real-time analysis were as follows: b-actin (see above); IkB (forward:
acactagaaaacttcagatgc, reverse: acacagtcatcatagggcag); il8 (forward: caatcc-
tagtttgatactccc, reverse: aattactaatattgactgtggag); NF-kB (forward: ccacaag-
caagaagctgaag, reverse: agatactatctgtaagtgaacc). C-myc primers have been
published previously (15). cDNA was amplified in three separate reactions
and each cDNA batch was aliquoted in triplicate into 96 well plates using the
appropriate PCR primers and the IQ Sybr-green supermix (Bio-Rad). Relative
Fig. 1. The TNF/NF-kB pathway. TNF activates NF-kB via a TNFR/Traf2/NIK/IKK pathway, antagonized by TRAF1. This results in IkK phosphorylating
IkB leading to its degradation. NF-kB is then free to cross the nuclear membrane (hence post-translational control). NF-kB then switches on its target
genes including IkB, resulting in a negative feedback loop.
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gene expression between samples was calculated through the inclusion of a
cDNA dilution series of a reference sample, amplified with each primer set
separately. In order to account for RNA loading differences between samples,
the measured gene expression was normalized against b-actin expression. The
t-test was used to assign statistical significance.
NF-kB reporter system
The ability of DCA to activate NF-kB was investigated using a luciferase
reporter system in which the luciferase gene was under the control of a NF-kB
dependent promoter (Stratagene, Cambridge, UK). In short, the OE33 cells
were seeded in triplicate into 6 well tissue culture flasks and the NF-kB
luciferase plasmid was transfected into them using the genejammer transfec-
tion reagent (Stratagene). Initial experiments validated the transfection using
a supplied positive control for NF-kB activity. The cells were then either
exposed to DCA for varying periods of time (0--4 h) or remained untreated.
After exposure, the cells were processed following the manufacturer's recom-
mendations to release the luciferase enzyme and the subsequent luciferase
expression was quantified with the Bright-Glo luciferase assay system
(Promega, Southampton, UK). Resulting luminescence was measured using a
luminometer (Anthos Labtech Instruments, Salzburg, Austria). Fold increases
were calculated based on the background luminescence of the untreated cells
(untreated cells were set up for each time point analysed). The t-test was used
to evaluate differences between the triplicate readings from treated and
untreated cells.
Results
DCA specifically switches on IkB and IL-8
RNA extracted from untreated OE33 cells and OE33 cells
treated for 24 h with 300 mM DCA at pH 7, was analysed
using five different pathway specific membrane arrays. By far
the most prominent of the DCA induced gene expression
changes were the switching on of IkB and IL-8. As IkB and
IL-8 are transcriptional targets of NF-kB, this suggests activa-
tion of NF-kB by DCA (as is demonstrated below). As shown
in Figure 2, using a cancer pathway array and a signal trans-
duction array, both IkB and IL-8 are substantially up-regulated
24 h after DCA treatment. Figure 2 also shows a number of
other changes in gene expression 24 h after DCA treatment
(mostly up-regulation), these (and other changes noted from
other arrays) are documented in Table I.
The gene expression alterations listed in Table I from the five
different arraysused, havebeengrouped into fourseparategroups
based on the function of the genes involved. As IL-8 (29) and
IkB (30) have previously been suggested to be transcriptional
Fig. 2. Membrane array analysis of DCA treated OE33 cells, 24 h post-exposure. (a) Cancer pathway arrays were used to study gene expression abnormalities
induced by 300 mM DCA relative to untreated OE33 cells. These example arrays show the up-regulation of the IkB and IL-8 genes by DCA. (b) Two example
signal transduction arrays are shown; those hybridized with cDNA from untreated OE33 cells and cDNA from OE33 cells 24 h after DCA exposure.
A number of other genes are up-regulated by DCA, particularly evident in the cancer pathway array in (a). These genes (and others) are identified in Table I.
Table I. Other DCA induced gene expression alterations
Gene "# Time point
NFkB related genes
Tumour necrosis factor alpha
induced protein (TNFaip)
"" 4--24 h
Flice inhibitory protein (FLIP,
Cflar, Casper)
" 24 h
Cellular proteases/invasion genes
Plasminogen activator,
Urokinase (Plau)
""" 1--24 h
Plasminogen activator receptor (PlauR) "" 24 h
Plasminogen activator inhibitor 1
(Serpine 1)
## 24 h
Serine protease inhibitor B5
(maspin, Serpine B5)
"" 24 h
Plasminogen activator inhibitor B2
(Serpine B2, PAI-2)
"" 24 h
Growth factors/receptors
Melanoma growth stimulating
activity (MGSA, Gro 1)
" 24 h
Vascular endothelial growth factor (VEGF) " 4--24 h
Epidermal growth factor
receptor (EGFR)
" 1--24 h
Adhesion molecules
b-Catenin " 1--24 h
Integrin B1, integrin A6 " 4--24 h
E-Cadherin " 1 h
Intercellular adhesion molecule (Icam) " 4--24 h
Neural cell adhesion molecule (Ncam) "" 1--4 h
This table contains a list of genes whose expression was consistently altered
after exposure to DCA. By consistent, we mean that the expression change
was evident on both duplicate array experiments (although no real-time PCR
data available). In the right hand column is the time point at which the
expression change was evident. The arrows in the central column reflect
the relative strength of the expression changes.
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targets of NF-kB, we have subsequently used IL-8 and IkB
expression as surrogates for NF-kB activation. In order to sup-
port the use of IL-8 and IkB as surrogates of NF-kB activation
we exposed cells to bile in the presence of an inhibitor of NF-kB,
pyrrolidine dithiocarbamate (PDTC). Figure 3a shows the result
of this experiment and demonstrates that inhibition of NF-kB
results in suppression of DCA induced IL-8 and IkB expression,
thus confirming the link between NF-kB activation and IL-8 and
IkB up-regulation. Figure 3b further demonstrates the activation
of NF-kB by bile acids, using a luciferase reporter system con-
taining NF-kB promoter elements. DCA (300 mM at neutral pH)
caused significant luciferase activity 1 h after incubation with the
cells bearing the reporter.
Time course study on DCA induced gene expression changes
In order to study the effect of DCA exposure duration on
the gene expression changes noted above (particularly IkB and
IL-8), a time course study was undertaken whereby OE33 cells
were exposed to 300 mM DCA for 1--24 h. For this study only
the cancer pathway finder array was employed, as this array
contained both the IkB and IL-8 genes. The results of this
study showed that the DCA induced expression of IkB and
IL-8 was first evident 4 h post-exposure. Real-time PCR was
used to confirm these findings and to quantify the increases in
gene expression (Figure 4a). NF-kB expression was also mea-
sured by real-time PCR, but did not change during the time
series, as expected. Figure 4a also shows examples of the
individual array signals for the IkB and IL-8 genes across
the time series. The fold increases in IkB and IL-8
gene expression as measured by real-time PCR, at 4 h were
46- and 16-fold, respectively. The similar figures at 24 h were
64- and 17-fold, respectively.
In order to assess the role of DCA dose level on the gene
expression patterns noted above, DCA exposures of 100 and
200 mM were also performed at the 4 h time point. IL-8 up-
regulation was employed here as a measure of NF-kB activa-
tion. Real-time PCR showed that the up-regulation of the IL-8
gene at 100 and 200 mM was 3.3- and 5.4-fold, respectively
(Figure 4b). Both these levels of up-regulation were statisti-
cally significant (P 5 0.05). The DCA induced activation
of NF-kB and up-regulation of IL-8 and IkB has also been
demonstrated by us in another cell line (OE21, derived from
a squamous cell carcinoma) (Harries et al., manuscript in
preparation). Therefore, these data coupled with reports of
NF-kB activation in colon cancer cells and hepatocytes
(26,27) demonstrate that the effect is not cell line specific.
The effect of pH on DCA induced gene expression
As reflux episodes usually occur in patients at acid pH, we
investigated whether lowering the pH of the bile to 4 (the
normal pH of the stomach) affected the changes in gene
expression noted above. Treating OE33 cells for 4 h with 300
or 200 mM DCA at pH 4 resulted in extensive cell death, hence
little RNA was available for expression analysis. Measuring
gene expression changes against a background of cytotoxicity
could lead to unreliable data. Therefore, DCA doses of 100 mM,
shown previously to bring about the same range of gene
expression changes as 300 mM (albeit at a lower level), were
employed at pH 4, as this dose produced little cytotoxicity.
Real-time data obtained from the analysis of IL-8 expression
in cells exposed to 100 mM DCA at pH 4 and 7 is shown in
Fig. 3. Demonstration that NF-kB is specifically activated by DCA. (a) The effect that an inhibitor of NF-kB (pyrrolidine dithiocarbamate) has on NF-kB
activation, as measured by IkB and IL-8 expression. Both levels of IL-8 gene expression inhibition are significant (P 5 0.001), whereas the inhibition of IkB is
only significant (P 5 0.05) at the 10 mM PDTC concentration. (b) Results of the NF-kB reporter system after exposure to DCA. An exposure of 1 h causes a
significant increase in NF-kB activity as measured with this reporter system (P 5 0.05).
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Figure 4c. This demonstrates the fact that DCA is only capable
of activating NF-kB (as seen by IL-8 expression) at neutral pH
and not at acid pH. The absence of NF-kB activation (IkB and
IL-8 expression) at acid pH was also noted when using the
cDNA arrays (results not shown). However, the cDNA arrays
did show that the oncogene c-myc is up-regulated after acidic
bile exposure (but not neutral bile exposure) as established
previously (15). Figure 5 shows the real-time PCR analysis of
c-myc expression 4 h after exposure to acidic and neutral bile,
demonstrating the statistically significant up-regulation of this
gene after acidic bile exposure, but not after exposure to acid
or bile alone. These data are consistent with that of Tselepis
et al. (15), who also showed that c-myc up-regulation peaked
at 24 h post-exposure to DCA. Hence DCA is capable of
activating two different oncogenic transcription factors
depending upon the pH of the media at the time of exposure.
Discussion
This study analysed the effects that physiological dose levels
of DCA had on gene expression in oesophageal cells in vitro.
We have shown that DCA specifically activates NF-kB, result-
ing in substantial up-regulation of NF-kB regulated genes
(particularly IkB and IL-8). This is the first report of bile
induced NF-kB activation in oesophageal cells; however,
NF-kB has been shown previously to play a major role in
carcinogenesis in other tissue types (22,31--34). Furthermore,
NF-kB activation has been shown to be correlated with chemo-
resistance (35,36), indeed inhibition of NF-kB improves
tumour shrinkage by chemotherapy (22,37), which may be an
effective avenue for cancer therapy (38). Inhibiting NF-kB
activation has been shown to result in increased apoptosis
(27) and blocking of the neoplastic process (39).
The fact that the bile acid DCA is capable of inducing
widespread gene expression abnormalities, particularly invol-
ving genes related to cell survival, proliferation and invasion
(Table I), adds weight to the argument that bile reflux is
important in cancer development in Barrett's patients. Impor-
tantly, DCA caused this at neutral pH only; this is in contrast to
reports that bile induces c-myc expression only at acidic pH
(15). Our data also show c-myc up-regulation with acidic bile,
but show that neutral bile exposures are important in carcino-
genesis in the oesophagus. The fact that we have shown DCA
to be active at neutral pH may have widespread implication for
patients with non-acid reflux, particularly those taking acid
suppressive drugs (e.g. PPIs). Although PPIs reduce oesopha-
geal exposure to both acid and duodenal contents (40), they
may also increase the relative concentrations of unconjugated
0
Fig. 4. Real-time PCR was used to confirm and quantify gene expression changes induced by DCA. (a) Real-time PCR analysis shows that IkB and IL-8
expression first occur 4 h post-exposure to DCA. Below the graph are the corresponding array signals from example membrane arrays for IkB and IL-8.
(b) Even the lowest dose of DCA (100 mM) induces a significant increase in IL-8 expression (P 5 0.05). (c) This figure shows that DCA's activation of NF-kB
(reflected in IL-8 expression) only occurs at neutral pH, not at acid pH. The left hand part of the graph shows the effect of 100 mM DCA at neutral pH,
whereas the right hand part shows the effect at acidic pH.
Fig. 5. c-myc expression after acidic bile exposure. Real-time PCR
expression levels of c-myc after exposure to acid, bile and acidic bile,
demonstrating that only the latter is capable of up-regulating c-myc
expression. These data are consistent with those of Tselepis et al. (15).
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bile acids (41) such as DCA, in the refluxate. This neutral pH
refluxate may then interfere with cell function through the
activation of molecules such as NF-kB. Hence it is possible
that the current practise of prescribing PPIs for reflux symp-
toms may be promoting carcinogenesis in these patients via
NF-kB activation. This is an area that warrants urgent further
investigation.
The bile acid DCA was shown here to cause gene expression
abnormalities involving proteins regulating anti-apoptosis,
invasion, cell proliferation and cell adhesion (Table I). Due
to space limitations, not all can be discussed here, but some of
these gene expression changes have been documented pre-
viously and are known to be caused by either NF-kB or bile
acids. As mentioned earlier, the activation of NF-kB by bile
has been demonstrated previously in colon cancer cells (26,27)
and hepatocytes (28). IL-8 has also been shown to be a
transcriptional target of NF-kB (29) and is known to be up-
regulated by NF-kB in gastric cells exposed to Helicobacter
pylori (33). IL-8 is known to be linked to angiogenesis initia-
tion (42), metastasis (43) and is capable of suppressing apop-
tosis (44). Other genes shown here to be up-regulated by bile
(Table I) have also been identified in previous studies. Bile has
been shown to induce the expression of the invasion factors
Plau and PlauR (27). Corresponding increases in Plau and
PlauR gene expression have also been identified in Barrett's
metaplasia and oesophageal cancer (45,46). EGFR and VEGF
have been identified previously as NF-kB transcriptional
targets (reviewed in 22) and are commonly over-expressed
in Barrett's tissues (47,48). The anti-apoptotic genes Flip
(49) and A20 (50) have also been shown to be up-regulated
by NF-kB, an anti-apoptotic agent itself. Finally, the adhesion
gene Icam has been shown to be up-regulated by NF-kB (51),
while intregrin adhesion proteins have been shown previously
to be up-regulated in Barrett's metaplasia (47). Increases in
cell adhesion are consistent with increased inflammation, as
elevated adhesion allows neutrophil attachment to epithelial
cells (52). The pattern of gene expression changes identified
here suggests that neutral bile exposure leads to gene expres-
sion alterations that are fundamental to almost every stage of
carcinogenesis.
Previous cytogenetic studies in our laboratory have shown
that NF-kB and IL-8's chromosome (chromosome 4) is speci-
fically amplified during cancer progression in Barrett's
patients (18,19). This selective expansion of cells bearing
extra copies of chromosome 4, may now be interpreted in
light of the potential mechanism of NF-kB mediated cell
survival. Bile has been demonstrated previously to select for
apoptosis resistant, NF-kB active clones, in colon cancer cells
in vitro (27). Hence, we speculate that in bile exposed Barrett's
tissues,cells thatgainoneextracopy(ormore)ofchromosome4,
proliferate in the presence of bile at the expense of cells with
a normal karyotype, which are forced into apoptosis. This
survival is due specifically to the elevated NF-kB levels.
Moreover, an elevated inflammatory response in neighbouring
cells is induced by the NF-kB mediated up-regulation of IL-8,
leading to even further increases in apoptosis in the surround-
ing tissue. In this model it is also interesting to note that a
whole family of IL-8 related chemokines (the CXC chemo-
kines) are located on chromosome 4 (53). Indeed Gro 1, a
member of this family is shown here to be up-regulated by
exposure to bile (Table I).
In conclusion, we have found that the unconjugated bile acid
DCA activates NF-kB, a survival factor known to be amplified
at the chromosome level in Barrett's progression. Interest-
ingly, bile activated NF-kB here at neutral pH only suggesting
that neutral bile reflux may play an important role in cancer
development in Barrett's patients.
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